The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on the addition of proposed new advisory statements for labels of over the counter (OTC) and registered complementary medicines containing menthol for dermal use, for inclusion in the Required Advisory Statements for Medicine Labels (RASML). The proposal to include advisory statements for menthol in RASML follows previously implemented requirements for advisory statements on labels of menthol-containing listed medicines.

For more information and to participate in the consultation, please visit consultation hub.

Timetable

The consultation opens on Tuesday 6 April 2021. Interested parties should respond by close of business, Tuesday 18 May 2021.

Enquiries

Any questions relating to submissions should be emailed to rasml@health.gov.au.